COVID-19: sudden and dramatic upsurge in the number of cases in India
DOI:
https://doi.org/10.18203/2394-6040.ijcmph20213047Keywords:
COVID-19, Second wave, India, Upsurge, Vaccine, Healthcare burdenAbstract
The second wave of coronavirus disease 2019 (COVID-19) in India, which commenced in March’21, continues to create a major crisis of medications, hospital beds, oxygen, and Intensive Care Units at very rapid rate which has placed the country on the verge of a humanitarian crisis. While no definite treatment for SARS-CoV-2 has been found, different types of vaccines have been manufactured which have shown some effectiveness in preventing disease progression and severity. The objective of this manuscript is to review the available data from the pandemic and highlight the factors that have contributed to the development of second wave in India which has led to crisis. In this review, using available scientific literature on various indexes such as PubMed, Google Scholar, Medline and news articles- where appropriate, we dive into understanding newer virus variants, vaccines and their effectiveness against new strains, overwhelming burden on the Indian healthcare system and socio-politico-environmental factors responsible for upsurge. The sudden upsurge in the number of cases is multifactorial, which includes virus variants, complacency in following COVID-19 appropriate behaviour, burden over the health care system, various socio-politico-environmental factors. As the definitive treatment is yet to be discovered, vaccination remains at the top.
Metrics
References
Darby, A. C., & Hiscox, J. A. (2021). Covid-19: variants and vaccination. BMJ (Clinical research ed.), 372, n771. https://doi.org/10.1136/bmj.n771
Bhatt, N. (2021, April 24). 'The horror is real': India faces oxygen crisis alongside world's highest COVID-19 caseload. The Globe and Mail. https://www.theglobeandmail.com/world/article-indias-covid-19-crisis-is-like-a-mad-train/.
Srivastava, S., Banu, S., Singh, P., Sowpati, D. T., & Mishra, R. K. (2021). SARS-CoV-2 genomics: An Indian perspective on sequencing viral variants. Journal of biosciences, 46(1), 22. https://doi.org/10.1007/s12038-021-00145-7
Mahase E. (2021). Covid-19: What new variants are emerging and how are they being investigated?. BMJ (Clinical research ed.), 372, n158. https://doi.org/10.1136/bmj.n158
Fontanet, A., Autran, B., Lina, B., Kieny, M. P., Karim, S., & Sridhar, D. (2021). SARS-CoV-2 variants and ending the COVID-19 pandemic. Lancet (London, England), 397(10278), 952–954. https://doi.org/10.1016/S0140-6736(21)00370-6
Farrer, M. (2021, April 21). Why is India seeing such a huge surge in Covid-19 cases? The Guardian. https://www.theguardian.com/world/2021/apr/21/why-is-india-seeing-such-a-huge-surge-in-covid-19-cases.
Naqvi, A. A. T., Fatima, K., Mohammad, T., Fatima, U., Singh, I. K., Singh, A., Atif, S. M., Hariprasad, G., Hasan, G. M., & Hassan, Md. I. (2020). Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1866(10), 165878. https://doi.org/10.1016/j.bbadis.2020.165878
CDC. (2020, February 11). Coronavirus Disease 2019 (COVID-19). Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-emerging-variants.html
Thiagarajan, K. (2021). Why is India having a covid-19 surge? BMJ, 373, n1124. https://doi.org/10.1136/bmj.n1124
Indian SARS-CoV-2 Genomic Consortia (INSACOG) | Department of Biotechnology. (n.d.). Retrieved May 12, 2021, from http://dbtindia.gov.in/insacog
Cherian, S., Potdar, V., Jadhav, S., Yadav, P., Gupta, N., Das, M., Das, S., Agarwal, A., Singh, S., Abraham, P., Panda, S., Mande, S., Swarup, R., Bhargava, B., Bhushan, R., Team, N. I. C., & Consortium, I. (Unpublished results). Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India. BioRxiv, 2021.04.22.440932. https://doi.org/10.1101/2021.04.22.440932
Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus: Cell. (n.d.). Retrieved May 3, 2021, from https://www.cell.com/cell/fulltext/S0092-8674(20)30820-5?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS0092867420308205%3Fshowall%3Dtrue
Volz, E., Hill, V., McCrone, J. T., Price, A., Jorgensen, D., O’Toole, Á., Southgate, J., Johnson, R., Jackson, B., Nascimento, F. F., Rey, S. M., Nicholls, S. M., Colquhoun, R. M., Filipe, A. da S., Shepherd, J., Pascall, D. J., Shah, R., Jesudason, N., Li, K., … Connor, T. R. (2021). Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell, 184(1), 64-75.e11. https://doi.org/10.1016/j.cell.2020.11.020
Yurkovetskiy, L., Wang, X., Pascal, K. E., Tomkins-Tinch, C., Nyalile, T. P., Wang, Y., Baum, A., Diehl, W. E., Dauphin, A., Carbone, C., Veinotte, K., Egri, S. B., Schaffner, S. F., Lemieux, J. E., Munro, J. B., Rafique, A., Barve, A., Sabeti, P. C., Kyratsous, C. A., … Luban, J. (2020). Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant. Cell, 183(3), 739-751.e8. https://doi.org/10.1016/j.cell.2020.09.032
Sarkar, R., Banerjee, A., Dutta, S., & Chawla-Sarkar, M. (Unpublished results). Emergence of SARS-CoV-2 stains harbouring the signature mutations of both A2a and A3 clade. MedRxiv, 2021.02.04.21251117. https://doi.org/10.1101/2021.02.04.21251117
Deng, X., Garcia-Knight, M. A., Khalid, M. M., Servellita, V., Wang, C., Morris, M. K., Sotomayor-González, A., Glasner, D. R., Reyes, K. R., Gliwa, A. S., Reddy, N. P., Martin, C. S. S., Federman, S., Cheng, J., Balcerek, J., Taylor, J., Streithorst, J. A., Miller, S., Kumar, G. R., … Chiu, C. Y. (Unpublished results). Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. MedRxiv, 2021.03.07.21252647. https://doi.org/10.1101/2021.03.07.21252647
Jangra, S., Ye, C., Rathnasinghe, R., Stadlbauer, D., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Chernet, R. L., Eaker, L. Q., Ferreri, E. D., Floda, D. L., Gleason, C. R., Kleiner, G., Jurczyszak, D., Matthews, J. C., Mendez, W. A., Mulder, L. C. F., … Schotsaert, M. (2021). SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. The Lancet Microbe, 0(0). https://doi.org/10.1016/S2666-5247(21)00068-9
Tortorici, M. A., Beltramello, M., Lempp, F. A., Pinto, D., Dang, H. V., Rosen, L. E., McCallum, M., Bowen, J., Minola, A., Jaconi, S., Zatta, F., De Marco, A., Guarino, B., Bianchi, S., Lauron, E. J., Tucker, H., Zhou, J., Peter, A., Havenar-Daughton, C., … Veesler, D. (2020). Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms. Science (New York, N.Y.), 370(6519), 950–957. https://doi.org/10.1126/science.abe3354
Kumar, V., Singh, J., Hasnain, S. E., & Sundar, D. (Unpublished results). Possible link between higher transmissibility of B.1.617 and B.1.1.7 variants of SARS-CoV-2 and increased structural stability of its spike protein and hACE2 affinity. BioRxiv, 2021.04.29.441933. https://doi.org/10.1101/2021.04.29.441933
GISAID - India. (n.d.). Retrieved May 17, 2021, from https://www.gisaid.org/phylodynamics/india/
Regeneron COVID-19 Dashboard. (n.d.). Retrieved May 17, 2021, from https://covid19dashboard.regeneron.com/?tab=Home&subTab=Asia
Forni, G., & Mantovani, A. (2021). COVID-19 vaccines: Where we stand and challenges ahead. Cell Death & Differentiation, 28(2), 626–639. https://doi.org/10.1038/s41418-020-00720-9
COVID-19 vaccines. (n.d.). Retrieved May 14, 2021, from https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccines
Vaccine information, ICMR New delhi—COVID-19 Vaccine. (n.d.). Retrieved May 19, 2021, from https://vaccine.icmr.org.in/covid-19-vaccine
About the Oxford COVID-19 vaccine. (n.d.). Retrieved May 23, 2021, from https://www.research.ox.ac.uk/article/2020-07-19-the-oxford-covid-19-vaccine
Knoll, M. D., & Wonodi, C. (2021). Oxford–AstraZeneca COVID-19 vaccine efficacy. The Lancet, 397(10269), 72–74. https://doi.org/10.1016/S0140-6736(20)32623-4
Mallapaty, S., & Callaway, E. (2021). What scientists do and don’t know about the Oxford–AstraZeneca COVID vaccine. Nature, 592(7852), 15–17. https://doi.org/10.1038/d41586-021-00785-7
Sputnik V, Covishield, Covaxin: What we know about India’s Covid-19 vaccines—BBC News. (n.d.). Retrieved May 15, 2021, from https://www.bbc.com/news/world-asia-india-55748124
Press Releases. (n.d.). Retrieved May 17, 2021, from https://www.drreddys.com/media/press-releases/
Yadav, P., Sapkal, G. N., Abraham, P., Deshpande, G., Nyayanit, D., Patil, D. Y., Gupta, N., Sahay, R. R., Shete, A., Kumar, S., Panda, S., & Bhargava, B. (Unpublished results). Neutralization potential of Covishield vaccinated individuals sera against B.1.617.1. BioRxiv, 2021.05.12.443645. https://doi.org/10.1101/2021.05.12.443645
Yadav, P. D., Sapkal, G. N., Abraham, P., Ella, R., Deshpande, G., Patil, D. Y., Nyayanit, D. A., Gupta, N., Sahay, R. R., Shete, A. M., Panda, S., Bhargava, B., & Mohan, V. K. (2021). Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees. Clinical Infectious Diseases, ciab411. https://doi.org/10.1093/cid/ciab411
Edara, V.-V., Lai, L., Sahoo, M. K., Floyd, K., Sibai, M., Solis, D., Flowers, M. W., Hussaini, L., Ciric, C. R., Bechnack, S., Stephens, K., Mokhtari, E. B., Mudvari, P., Creanga, A., Pegu, A., Derrien-Colemyn, A., Henry, A. R., Gagne, M., Graham, B. S., … Suthar, M. S. (Unpublished results). Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant. BioRxiv, 2021.05.09.443299. https://doi.org/10.1101/2021.05.09.443299
Singh, A. K., Phatak, S. R., Singh, N. K., Gupta, A., Sharma, A., Bhattacharjee, K., & Singh, R. (Unpublished results). Antibody Response after First-dose of ChAdOx1-nCOV (CovishieldTM®) and BBV-152 (CovaxinTM®) amongst Health Care Workers in India: Preliminary Results of Cross-sectional Coronavirus Vaccine-induced Antibody Titre (COVAT) study. MedRxiv, 2021.04.07.21255078. https://doi.org/10.1101/2021.04.07.21255078
Madhi, S. A., Baillie, V., Cutland, C. L., Voysey, M., Koen, A. L., Fairlie, L., Padayachee, S. D., Dheda, K., Barnabas, S. L., Bhorat, Q. E., Briner, C., Kwatra, G., Ahmed, K., Aley, P., Bhikha, S., Bhiman, J. N., Bhorat, A. E., du Plessis, J., Esmail, A., … Izu, A. (0). Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant. New England Journal of Medicine, 0(0), null. https://doi.org/10.1056/NEJMoa2102214
Irfan, N., & Chagla, Z. (2021). In South Africa, a 2-dose Oxford/AZ vaccine did not prevent mild to moderate COVID-19 (cases mainly B.1.351 variant). Annals of Internal Medicine. https://doi.org/10.7326/ACPJ202105180-050
Emary, K., Golubchik, T., Aley, P. K., Ariani, C. V., Angus, B., Bibi, S., Blane, B., Bonsall, D., Cicconi, P., Charlton, S., Clutterbuck, E. A., Collins, A. M., Cox, T., Darton, T. C., Dold, C., Douglas, A. D., Duncan, C., Ewer, K. J., Flaxman, A. L., Faust, S. N., … Oxford COVID-19 Vaccine Trial Group (2021). Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet (London, England), 397(10282), 1351–1362. https://doi.org/10.1016/S0140-6736(21)00628-0
Khoury, D.S., Cromer, D., Reynaldi, A. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med (2021). https://doi.org/10.1038/s41591-021-01377-8
Singh A, Deedwania P, Vinay K, Chowdhury AR, Khanna P (2020) Is India's Health Care Infrastructure Sufficient for Handling COVID 19 Pandemic?. Int Arch Public Health Community Med 4:041. doi.org/10.23937/2643-4512/1710041
Golechha, M. (2021). India should ramp up its emergency medicine and critical care infrastructure to combat COVID-19. Postgraduate Medical Journal, 97(1146), 266. https://doi.org/10.1136/postgradmedj-2020-138249
Hospital beds (per 1,000 people)—India | Data. (n.d.). Retrieved May 6, 2021, from https://data.worldbank.org/indicator/SH.MED.BEDS.ZS?end=2018&locations=IN&start=1960&view=chart
Medical doctors (per 10 000 population). (n.d.). Retrieved May 6, 2021, from https://www.who.int/data/gho/data/indicators/indicator-details/GHO/medical-doctors-(per-10-000-population)
Sharma, N. C. (2020, October 19). India is in throes of community transmission, admits Vardhan. Mint. https://www.livemint.com/news/india/india-is-in-throes-of-community-transmission-admits-vardhan-11603072987749.html
Sunil, R., Bhatt, M. T., Bhumika, T. V., Thomas, N., Puranik, A., Chaudhuri, S., & Shwethapriya, R. (2021). Weathering the Storm: Psychological Impact of COVID-19 Pandemic on Clinical and Nonclinical Healthcare Workers in India. Indian Journal of Critical Care Medicine : Peer-Reviewed, Official Publication of Indian Society of Critical Care Medicine, 25(1), 16–20. https://doi.org/10.5005/jp-journals-10071-23702
Hamid, H., Abid, Z., Amir, A., Rehman, T. U., Akram, W., & Mehboob, T. (2020). Current burden on healthcare systems in low- and middle-income countries: Recommendations for emergency care of COVID-19. Drugs & Therapy Perspectives, 1–3. https://doi.org/10.1007/s40267-020-00766-2
Rekha M (2020) COVID-19: Health Care System in India. Health Care: Current Reviews S1:262. doi: 10.35248/2375-4273.20.S1.262.
Schneider, M., Altersberger, M., Binder, C., Hengstenberg, C., & Binder, T. (2021). The COVID-19 burden for health care professionals: Results of a global survey. European Journal of Internal Medicine, 83, 96–98. https://doi.org/10.1016/j.ejim.2020.11.011
Behera, D., Praveen, D., & Behera, M. R. (2020). Protecting Indian health workforce during the COVID-19 pandemic. Journal of Family Medicine and Primary Care, 9(9), 4541–4546. https://doi.org/10.4103/jfmpc.jfmpc_925_20
India rolls out the world’s largest COVID-19 vaccination drive. (n.d.). Retrieved May 20, 2021, from https://www.who.int/india/news/feature-stories/detail/india-rolls-out-the-world-s-largest-covid-19-vaccination-drive
Risk of Covid-19 spread during ongoing wedding season, say experts. (2021, February 17). Hindustan Times. https://www.hindustantimes.com/india-news/risk-of-covid-19-spread-during-ongoing-wedding-season-say-experts-101613541960625.html
Superspreader events like weddings behind new Covid surge: Govt panel. (2021, March 19). Hindustan Times. https://www.hindustantimes.com/india-news/superspreader-events-like-weddings-behind-new-covid-surge-govt-panel-101616177606318.html
Coronavirus in India: Latest Map and Case Count. (n.d.). Retrieved May 20, 2021, from https://www.covid19india.org
India Covid crisis: Did election rallies help spread virus? (2021, April 29). BBC News. https://www.bbc.com/news/56858980
Haridwar Kumbh Mela 2021: Gathering starts today—check dates of shahi snan, ganga snan, Covid 19 guidelines and more. (2021, April 1). Zee Business. https://www.zeebiz.com/india/news-haridwar-kumbh-mela-2021-gathering-starts-today-check-dates-of-shahi-snan-ganga-snan-covid-19-guidelines-and-more-154035
Covid-19 vaccination drive for people above the age of 45 begins from today. (2021, April 1). Hindustan Times. https://www.hindustantimes.com/india-news/covid19-vaccination-drive-for-people-above-the-age-of-45-begins-from-today-101617242491029.html
Vaccination of 18-44 year olds takes off in Capital. (2021, May 4). Hindustan Times. https://www.hindustantimes.com/cities/delhi-news/vaccination-of-18-44-year-olds-takes-off-in-capital-101620073625676.html
88% of Covid-19 fatalities, 40% of cases in 45+ age group: Govt data. (2020, December 18). Hindustan Times. https://www.hindustantimes.com/india-news/88-of-covid-fatalities-40-of-cases-in-45-age-group-govt-data/story-0RvZ2kT1CXMRonZjl6pGlL.html
Half of Covid patients in Maharashtra under-40, only 18% elderly positive. (n.d.). The New Indian Express. Retrieved May 3, 2021, from https://www.newindianexpress.com/nation/2021/apr/03/half-of-covid-patients-in-maharashtra-under-40-only-18-elderly-positive-2285162.html
Downloads
Published
How to Cite
Issue
Section
